Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
RESEARCH TOOLSreports
Holding DE:9IP1?
Track your performance easily
See the Price Targets and Ratings of:
9IP1 Analyst Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9IP1 Stock 12 Month Forecast
Average Price Target
€42.38
▲(302.06% Upside)
| Highest Price Target€62.72 | Average Price Target€42.38 | Lowest Price Target€27.98 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
Reiterated
12/20/24
Jefferies
Initiated
12/18/24
Leerink Partners
Reiterated
12/11/24
Bank of America Securities
Reiterated
11/19/24
LifeSci Capital
Reiterated
11/19/24
TD Cowen
Reiterated
11/19/24
Scotiabank
Reiterated
11/19/24
Needham
Reiterated
11/19/24
Cantor Fitzgerald
Reiterated
11/18/24
William Blair
Reiterated
11/18/24
J.P. Morgan
€47.28
Buy
348.56%
Upside
Reiterated
11/18/24
Optimistic Long-Term Outlook for Rocket Pharmaceuticals Amid Promising Study Results and Undervalued Stock Potential
Canaccord Genuity
€37.63
Buy
257.02%
Upside
Reiterated
11/18/24
Promising Long-Term Data and Upcoming Catalysts Drive Buy Rating for Rocket Pharmaceuticals
Morgan Stanley
€43.42
Buy
311.94%
Upside
Reiterated
11/18/24
Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
Goldman Sachs
€32.81→€27.98
Hold
165.48%
Upside
Reiterated
11/08/24
Rocket Pharmaceuticals (RCKT) PT Lowered to $29 at Goldman SachsGoldman Sachs analyst Richard Law lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $29.00 (from $34.00) while maintaining a Neutral rating.
Stifel Nicolaus
€46.31
Buy
339.41%
Upside
Reiterated
11/08/24
Stifel Nicolaus Remains a Buy on Rocket Pharmaceuticals (RCKT)
Best Analysts Covering Rocket Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy DE:9IP1 and Sell After:
1 Month
xxx
Success Rate
7/12 ratings generated profit
Average Return
+7.43%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +7.43% per trade.
3 Months
xxx
Success Rate
7/12 ratings generated profit
Average Return
+9.27%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +9.27% per trade.
1 Year
Success Rate
8/13 ratings generated profit
Average Return
+12.42%
reiterated a buy rating last month
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +12.42% per trade.
2 Years
xxx
Success Rate
7/31 ratings generated profit
Average Return
-19.70%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.58% of your transactions generating a profit, with an average return of -19.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9IP1 Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
13
13
13
23
21
Buy
6
6
6
7
5
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
20
20
31
27
Each month's total comprises the sum of three months' worth of ratings.
9IP1 Financial Forecast
9IP1 Stock Forecast FAQ
What is DE:9IP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is €42.38.
What is DE:9IP1’s upside potential, based on the analysts’ average price target?
Rocket Pharmaceuticals has 302.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rocket Pharmaceuticals a Buy, Sell or Hold?
Rocket Pharmaceuticals has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Rocket Pharmaceuticals’s share price target?
The average share price target for Rocket Pharmaceuticals is €42.38. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €62.72 ,and the lowest forecast is €27.98. The average share price target represents 302.06% Increase from the current price of €10.54.
The highest analyst share price target is €62.72 ,and the lowest forecast is €27.98. The average share price target represents 302.06% Increase from the current price of €10.54.
What do analysts say about Rocket Pharmaceuticals?
Rocket Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of Rocket Pharmaceuticals?
To buy shares of DE:9IP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.